首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >CHALLENGES AND NEW DIRECTIONS IN OBESITY MANAGEMENT:
【24h】

CHALLENGES AND NEW DIRECTIONS IN OBESITY MANAGEMENT:

机译:肥胖管理的挑战和新方向:

获取原文
           

摘要

Obesity is a growing health problem worldwide, and it is associated with serious medical and psychosocial comorbidities, impairment of health-related quality of life (HRQoL) and an increased risk of mortality. This article aims to discuss challenges faced by health-care providers when managing patients with obesity and to highlight sustainable policies in clinical practice and future research. All health professionals dealing with obesity should consider lifestyle-modification programmes within a multidisciplinary setting as the key element of weight management. However, standardisation is needed in terms of nature, content and duration of these programmes in order to facilitate their implementation in clinical practice at different levels. Moreover, health professionals should be aware that these programmes, for patients indicating “non-response,” can be combined with recently approved anti-obesity drugs such as liraglutide, naltrexone/bupropion, lorcaserin and phentermine/topiramate, as well as with relatively less invasive bariatric surgery techniques such as Lap Band, endoscopic sleeve gastroplasty and gastric bypass. In any case, neither anti-obesity medication nor bariatric surgery should be considered as a miracle treatment in itself. At the same time, the field of obesity is still lacking in literature on some hot topics that need further investigation, including (i) a new phenotype termed sarcopenic obesity, to clarify its definition, potential health consequences and eventual treatment if necessary; (ii) issues that go beyond body weight, for instance, HRQoL that has been poorly studied in some populations affected by obesity; and (iii) the long-term effect of sleeve gastrectomy technique, which is becoming the most commonly used bariatric surgical procedure, perhaps to be studied using long-term randomised controlled trials that guarantee completeness of follow-up, in order to avoid misunderstanding and bias in interpretation of results.
机译:肥胖是全球范围内日益严重的健康问题,与严重的医学和心理社会合并症,与健康有关的生活质量(HRQoL)受损以及死亡风险增加相关。本文旨在讨论医疗保健提供者在管理肥胖症患者时面临的挑战,并强调在临床实践和未来研究中的可持续政策。所有处理肥胖症的卫生专业人员都应在多学科环境中考虑改变生活方式的方案,将其作为体重管理的关键要素。但是,需要在这些程序的性质,内容和持续时间方面进行标准化,以促进它们在不同级别的临床实践中的实施。此外,卫生专业人员应意识到,对于那些表示“无反应”的患者,这些计划可以与最近批准的抗肥胖药(例如利拉鲁肽,纳曲酮/安非他酮,氯卡色林和芬特明/托吡酯)结合使用,并且相对较少有创减肥手术技术,例如膝带,内窥镜袖胃成形术和胃搭桥术。无论如何,抗肥胖药和减肥手术本身都不应该被视为奇迹疗法。同时,关于某些热门话题的文献仍缺乏肥胖领域,需要进一步研究,其中包括:(i)一种新的表型,称为少肌症肥胖症,以阐明其定义,潜在的健康后果以及必要时的最终治疗方法; (ii)超出体重的问题,例如,HRQoL在某些受肥胖影响的人群中研究不足; (iii)套筒胃切除术技术的长期效果,该技术正在成为减肥手术中最常用的方法,也许可以通过长期的随机对照试验来研究,以确保随访的完整性,以避免误解和误诊。结果解释的偏见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号